# Literaturliste

## Antivirale Effekte der Süßholzwurzel

*Jens Bielenberg*

Erschienen in der CO.med 12/2020, S. 38-40.

[1] Pompei R, Flore O, Marccialis M.A., Pani A, Loddo B. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979, 281: 689-90.

[2] Crance J.M., Leveque F, Biziagos E. Studies on the mechanism of action of glycyrrhizin against hepatitis C virus replication. Antiviral research 1994, 2: 63-76

[3] Pompei R., Pani A, Flore, O, Loddo B. Antiviral activity of glycyrrhizic acid Experientia 1980, 36: 304.

[4] Vichkanowa VA, Goryunova LV. C.A.1973,78: 155107.

[5] Badam L. In Vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid on Japanese encephalitis Virus. J Commun Dis 1979, 29(2) : 91-99.

[6] Harada S, Maekawa T, Haneda E, Morikawa Y, Nagata N, Ohtsuki K. Biochemical charakterisation of recombinant HIV-1-reverse Transcrptase (rRT) as a glycyrrhizin-binding Protein and the CK-II-mediated stimulation of rRT activity potently inhibited by glycyrrhetinic acid derivate. Biological and Pharmaceutical Bulletin 1998, 21(12): 1282-85.

[7] Wildhirt, E. Ein neuer Weg in der Behandlung chronisch entzündlicher Lebererkrankungen: Glycyrrhizinsäure . Arzt und Krankenhaus 1988,12: 383-7.

[8] Kiso Y, Tohkin M, Hikino H, Hattori M, Sakamoto T, Namba T. Mechanism of antihepatotoxic Activity of Glycyrrhizin. I:Effect on free radical Generation and Lipid Peroxidation. Planta Med 1984,50 : 298-302.

[9] Abe N, Ebina T, Ishida N. Interferon Induction by Glycyrrhizin and Glycyrrhetinic acid in Mice. 1982 Microbiol Immunol, 26 (6) : 535-539.

[10] Shibata S. A drug over the Milennia Pharmacognosy, Chemistry and Pharmacology of Licorice 2000 Yakugaku Zasshi 120(10), 849-862.

[11] Ashfad UA, Qasim M, Yousaf MZ et al. Glycyrrhizin as antiviral agent against Hepatitis C Virus. J Tranl Med 2011,18(9):112.

[12] Curelli F., Friedman-Kein A., Flore O.: Glycyrrhizic acid alters Kaposi-Sarcoma-associated herpesvirus latency, triggering p53 mediated apoptosis in transformed B lymphocytes. The Journal of Clinical Investigation 2005, 115 (3) 642–650.

[13] Laconi S, Madeddu M, Pompei R. Autophagy Activation and antiviral activity by a Licorice Triterpen Phytother Res 2014 ,28(12):1890-2.

[14] Pompei R, Laconi S, Ingianni A. Antiviral properties of Glycyrizic acid and its semisynthetic derivates. Mini Rev Med Chem 2009 , 9(8):996-1001.

[15] Cinatl J, Michaelis M, Doerr HW. The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants. Med Microbiol Immunol. 2007;196:181–190.

[16] Antiviral Spot of Excellence " (ASPEX) in Wien, 2011 Wolkersdorfer A;et al. Glycyrrhizin inhibits influenz A virus uptake into the cell. Antivir.Res 2009 83(2):171

[17] Radulovic A , Rossini A et al. CD69 reguliert durch Expression der Chemokine CCL-1 und CCL-19 Retention von Lymphozyten in Mesenterischen Lymphknoten. Z Gastroenterol 2012 Doi :10.1055 /s -0032.

[18] Cheel J, et al. Licorice infusion: Chemical profile and effects on the activation of human lymphocytes. Pharmacogn Mag 2010, 6(21): 26-33.

[19] Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of licorice roots, and replication od SARS-assicated coronavirus.
Lancet 2003,361(9374) :2045-2046.

[20] Lazo P, Santos C. Interference with p 53functions in human viral infections, a target for novel antiviral strategies? Rev Med Vir 2011, 21(5).

[21] Aloni Grinstein R, Charni-Nata M, Solomon H, Rotter V. P53 and the viral connection: back into the future. Rev Canc 2016,10(6).

[22] Hao Z, Fu F, Cao L, Guo L, Liu J, Xue M, Feng L. Tumor supressor p53 inhibits porcine edodemic diarrhea virus infection via interferon –mediated antiviral immunity. Mol Immunol 2019 ,108 :68 -74.

[23] Yu JY, HA JY, Kim KM et al. Anti-inflammatory activities of licorice extract and its active compounds,glycyrrhizic acid, liquiritin and liquiritigenin, in BV2-cells and mice liver. Molecules 2015, 20(7):3041-54.

[24] Yang BS, Ma Y-J, Wang Y, et al. Protective effect and mechanism of Stronger Neo-Minophagen C against fulminant hepatic failure. World Gastroenterol 2007,Jan 21;13(3):462-6.

[25] Yang R, Yuan B-C, Ma Y-S, Zhou S.Liu Y. The anti-inflammatory activity of licorice, a widely used Chinese herb. Rev PharmBiol 2017,55(1):5-18.

[26] Kuba K, Imai Y, Rao S, Jiang C, Penninger J.Lessons from SARS: Control of acute lung failure by the SARS Receptor ACE. J Mol Med 2006,84(10):814-20.

[27] Jia H. Pulmonary Angiotensin-Converting Enzyme2 (ACE2) and inflammatory lung disease. Review shock,2016,46(3):23-48

[28] Bielenberg J. Intoxikationen durch Lakritzenverzehr. Der Allgemeinarzt. Verlag Kirchheim1992. 14:509-515.

[29] AraseY, Ikeda K, Murashima N. The long term efficiency of Glycyrrhizin. In: chronic hepatitis C patients Cancer 1997;79:1494-1500.

[30] Van Rossum T, Vulto A, Hop W et al. Intravenous Glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled phase I/II trial. Journal of Gastroenterology & Hepatology 1999;14:1093-9.

[31] Van Rossum T, Vulto A, Hop W et al. Glycyrrhizin induced reduction of Serum-ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001;96(8):2432-7.

[32] Zhang L, Cui Z, Wang B. Therapeutic effects of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver disease. Hepatology Research 2000;16:145-154.

[33] Lino S, Tango T, Matsushima T et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhoses. Histology Research 2001;19:31-40.

[34] Tandon A, Tandon BN, Bhujwala RA. Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: A pilot study. Hepatology Research 2001; 20:1-8.

[35] Tsubota A, Kumada H, AraseY et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C Virus infection. European J of Gastroenterology &Hepatology 1999,11(10:1077-18.

[36] Mendes –Silva W, Assafim M, Ruta B, Monteiro R. et al. Antithrombotic effect of Glycyrrhizin, a plant-derived Thrombin Inhibitor. Thromb Res 2003.

[37] Francschetti IM, Monteiro RQ, Guimaraes JA. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun 1997;235:259 -63.

[38] Bielenberg J. Influenza A: Oxidativer Stress, Virusreplikation und Krankheitsverlauf. Journal für die Apotheke 2018.

[39] Michaelis M, Geiler J, Naczk P, Sithisarn P, Leutz A, Doerr HW, et al. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One. 2011;6:e19705.

[40] Tong T, Hu H, Zhou J, Deng S, Zhang X, Tang W, et al. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms. Small. 2020:e1906206.

[41] Liu F, Xu M,Wu J, Luo D, et al. Prognostic value of interleukin -6, C-reactive protein , and procalcitonin in patients with COVID-19. J.Clin. Virol 2020;127:104370.

[42] Chen XX, Zhou HX, Qi WB, et al. Antiviral effects of the combination of Glycyrrhizin and Ribavarin against Influenza A H1N1 Virus infection in Vivo 2015. 50(8):966-72